BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment option for patients with acute myeloid leukemia (AML). During transplantation, patients undergo a period of severe neutropenia, which puts them at high risk for infectious complications. However, the impact of patient colonization with multidrug-resistant organisms (MDRO) on overall survival remains unclear. METHODS: In this retrospective, single-center study, the authors analyzed data from 264 patients with AML who underwent a first allo-HSCT between January 2006 and March 2016 at their institution. Primary endpoints were overall survival and nonrelapse-related mortality. RESULTS: One hundred forty-two of 264 patients (53.8%) were colonized by at least 1 MDRO, mainly with vancomycin-resistant Enterococcus faecalis/faecium (n 5 122). The characteristics of colonized patients did not differ from those of MDRO-negative patients with respect to median age (53.5 vs 53 years), cytogenetic risk according to European LeukemiaNet criteria, remission status before allo-HSCT (first or second complete remission: 55.7% vs 60.7%, respectively; active disease: 44.4% vs 39.3%, respectively), donor type, or hematopoietic cell transplantation-comorbidity index (HCT-CI). Compared with noncolonized patients, MDRO-positive patients had an inferior probability of survival at 5 years (43.3% vs 65.5%; P 5 .002), primarily because of a higher cumulative incidence of nonrelapse-related mortality (33.9% vs 9.4%; P < .001). Death caused by infections occurred in 15.5% of colonized patients versus 4.9% of noncolonized patients. There was no difference in the cumulative incidence of relapse in MDROpositive versus MDRO-negative patients (33.8% vs 42.1%, respectively; P 5 .798). CONCLUSIONS: The current data emphasize the importance of regular MDRO screenings and prompt further investigations into the impact of colonization with MDRO on the immune system after allo-HSCT. Cancer 2018;124:286-96.
INTRODUCTION
Acute myeloid leukemia (AML), a malignant neoplasm of early hematopoietic progenitor cells, is an aggressive disease and is always fatal if untreated. For patients with relapsed, therapy-refractory, or cytogenetically high-risk AML, an allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only (potentially) curative treatment option. 1 However, allo-HSCT is burdened with a significant risk of morbidity and mortality, particularly because of infection and graftversus-host disease (GvHD). 2, 3 During allo-HSCT, patients undergo a period of severe neutropenia lasting for 2 or 3 weeks in which bacterial infections are common; in 30% of all patients, bloodstream infections occur, 4, 5 with a mortality of up to 25%. 6 Multidrug-resistant organisms (MDRO), namely, vancomycin-resistant Enterococcus faecium/faecalis (VRE), methicillin-resistant Staphylococcus aureus (MRSA), and multidrug-resistant Gram-negative bacteria (MDRGN), increasingly affect patients who receive treatment in hospitals. Patients suffering from hematologic malignancies are especially at risk because of therapy-related and disease-related immunosuppression. Infections from MDRO lead to higher mortality compared with infections from fully susceptible organisms. 7, 8 In recent years, case numbers of MDRO infections are on the rise, which is believed to be caused mostly by the widespread use of antibiotics in animals and humans. 9 One of the main risk factors for an MDRO infection is prior colonization status with an MDRO. 10, 11 Because most patients require prolonged antibiotic treatments during AML induction therapy, those who undergo allo-HSCT are at high risk of already being colonized by an MDRO before transplantation.
However, there is controversy in the literature with regard to the impact of MDRO colonization on the outcome of patients who undergo allo-HSCT. [12] [13] [14] [15] Recently, we demonstrated that the detection of MDRO colonization was strongly associated with worse survival compared with noncolonized patients. 16 Therefore, in the current study, we retrospectively assessed outcomes of patients with AML after allo-HSCT at our institution and investigated whether MDRO colonization affected outcomes after allo-HSCT because of infectious-related death.
MATERIALS AND METHODS

Study Design and MDRO Definition
We retrospectively reviewed all consecutive patients with AML who underwent a first allo-HSCT at our institution between January 2006 and March 2016. Patients who had other underlying diseases or underwent previous allo-HSCT were excluded.
All patients were screened for MDRO on the day of admittance and weekly thereafter during hospitalization for allo-HSCT by rectal, pharyngeal, and nasal swabs. Colonization was defined as the detection of an MDRO in at least 1 swab. In our study, MDRO was defined as vancomycin-resistant E. faecium/faecalis (VRE), methicillin-resistant Staphylococcus aureus (MRSA), and multidrug-resistant Gram-negative bacteria (MDRGN). MDRGN had been described previously as Enterobacteriaceae with extended-spectrum b-lactamase (ESBL)-like phenotype and Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa resistant against piperacillin; any third-generation or fourth-generation cephalosporin; and fluoroquinolones with or without carbapenems.
17,18
Detection of MDRO and Analysis of Resistance All laboratory procedures were performed under qualitycontrolled criteria (laboratory accreditation according to International Organization for Standardization [ISO] 15189:2007 standards; certificate no. D-ML-13102-01-00, valid through January 25, 2021). For MDRGN and VRE detection, rectal swabs were collected using culture swabs with Amies collection and transport medium (Hain Lifescience, Nehren, Germany) and were streaked onto selective Gram-negative agar plates (eg, CHROMagar ESBL plates; Mast Diagnostica, Paris, France) as well as selective VRE agar plates (eg, ChromID VRE agar; bioMerieux, Nurtingen, Germany), respectively. For detection of MRSA, nasal swabs were streaked onto selective MRSA agar plates (eg, Brilliance MRSA Agar; Oxoid, Wesel, Germany). Species were identified by biochemical identification systems or by matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) analysis (API identification systems, VITEK MS; bioMerieux). Antibiotic susceptibility was tested according to Clinical and Laboratory Standards Institute (CLSI) guidelines using VITEK 2 and/or antibiotic gradient tests (bioMerieux) as well as an agar-diffusion method. In case of Gram-negative, carbapenem-resistant isolates, genes that encode carbapenemases are routinely detected using polymerase chain reaction analysis and subsequent sequencing from carbapenem-resistant Enterobacteriaceae, including the bla (b-lactamase) genes for carbapenemases NDM (class A nonmetallo carbapenemase), VIM (Verona integron-encoded metallo-b-lactamase), IMP (imipenem-resistant Pseudomonas), oxacillinase-84 (OXA-48)-like, and KPC (Klebsiella pneumoniae carbapenemase) as well as OXA-23, OXA-24, and OXA-58 for A. baumannii.
19,20
Clinical Characteristics and Definitions
Transplantation procedures were performed according to local protocols: For the immediate transplantation period (from day 25 to neutrophil recovery), all patients were admitted to a dedicated transplantation unit, which provides a protected environment (high-efficiency particulate air [HEPA]-filtered, clean-air rooms). Routine measures included insertion of a central venous line and antiinfective prophylaxis with cefotaxime, cotrimoxazol, acyclovir, and an echinocandin or broad-spectrum azole, respectively. In case of fever or other clinical signs of infection, the prophylactic antibiotic regimen was routinely changed to piperacillin/tazobactam in patients without colonization. In patients with colonization who had an MDRO, the antibiotic treatment regimen was modified according to the resistance profile of the colonizing organism. In each fever episode, blood samples were collected into culture bottles (BD BACTEC Lytic/10 Anaerobic/F and BD BACTEC Plus Aerobic/F; Becton Dickinson, Heidelberg, Germany). Conditioning for allo-HSCT was defined as myeloablative or reduced-intensity conditioning according to Bacigalupo et al and Giralt et al. 21, 22 The cytogenetic risk of AML (favorable, intermediate I/II, or adverse) was assessed according to the European LeukemiaNet (ELN) score. 23 Mucositis was defined and graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events. 24 To classify pre-existing conditions, the hematopoietic stem cell transplantation-specific comorbidity index (HCT-CI) score was calculated. 25 Acute GvHD (aGvHD) and chronic GvHD (cGvHD) were assessed using standard definitions. 26, 27 According to the US Centers for Disease Control and Prevention, blood stream infection (BSI) was defined as 1 or more positive blood culture results, except for coagulase-negative staphylococci, for which 2 consecutive positive blood cultures were required. 28 
Endpoints
The primary endpoints of the study were overall survival (OS) and nonrelapse related mortality (NRM), which was defined as death without relapse of AML. Secondary endpoints were: rate of neutropenic fever, admission to an intensive care unit (ICU) during allo-HSCT, and disease relapse, which was defined as a recurrence of >5% blasts in the bone marrow. The use of medical records for the analysis presented here was approved by the local ethics committee (approval number: SHN-02-2017).
Statistical Analysis
Statistical analysis was performed using R version 3.3.2 (packages "cmprsk" and "survival"; R Foundation for Statistical Computing, Vienna, Austria) and SPSS (version 24.0; IBM Corporation, SPSS Institute Inc. Chicago, IL). For univariate analysis, continuous variables were compared using the Mann-Whitney U test, and categorical variables were compared using the Fisher exact test and the chi-square test. The Kaplan-Meier method was used to calculate survival curves and the curves were compared using the log-rank test. To test the competing risks for NRM and relapse, the model of Gray and Fine was used (Gray test), and cumulative incidence curves were drawn. Multivariate analysis was used to assess the independent association with mortality of different variables using Cox proportional hazards.
RESULTS
Patient Characteristics
An overview of patient characteristics is provided in Table 1 , we observed no differences between the patients with and without colonization, except for the sex distribution: within the colonized group, 65.5% of patients were men, whereas men constituted only 51.6% of the noncolonized group. This difference was statistically significant (P 5 .024).
Microbiologic Findings and TransplantationRelated Characteristics
One hundred forty-two of 264 patients (53.8%) were colonized by at least 1 MDRO, in the vast majority by VRE (122 of 142 patients; 85.9%). Twenty of 142 patients (14.1%) were colonized with Escherichia coli, 5 of 142 (3.5%) were colonized with K. pneumoniae, 3 of 142 (2.1%) were colonized with Enterobacter cloacae, 1 of 142 (0.7%) were colonized with Citrobacter freundii, and all displayed a resistance phenotype against piperacillin, third-generation or fourth-generation cephalosporin, and fluoroquinolones (ESBL/FQ). P. aeruginosa with resistance against piperacillin, third-generation or fourthgeneration cephalosporin, fluoroquinolones, and also against carbapenems was detected in 6 of 142 patients Original Article (4.2%). Furthermore, 2 of 142 patients (1.4%) tested positive for E. coli, 2 of 142 (1.4%) tested positive for E. cloacae, 2 of 142 (1.4%) tested positive for K. pneumonia, and each expressed an ESBL phenotype with an additional carbapenem resistance. Four of 142 patients (2.8%) tested positive for MRSA. Of these, 25 of 142 (17.6%) were colonized with 2 MDROs, and none had more than 2 MDROs (Supporting Table 1 ; see online supporting information). Rectal colonization was detected in 96.5% of patients, and in nasal/pharyngeal colonization was detected in 21.1%. In 52 of 142 colonized patients (36.6%), the MDRO was detected on admission for allo-HSCT; and, in 90 of 142 colonized patients (63.4%), the MDRO was detected later during the hospital stay for allo-HSCT.
Transplantation-related characteristics are summarized in Table 2 . The median engraftment times for neutrophils (18 days; range, 9-36 days) and for platelets (19 days ) and significantly higher rates of grade 3 and 4 aGvHD (13.5% vs 5%; P 5 .020) than those without colonization, whereas the rates of cGvHD and severe cGvHD did not differ between patients with and without colonization.
Outcomes
The details of patient outcomes are provided in Table 3 , and Kaplan-Meier curves are presented in Figure 2 . The median length of follow-up for patients who remained alive after allo-HSCT in our study was 46. (Fig. 3A) . The cumulative incidence of relapse at 60 months was 33.6% (95% CI, 27.3%-39.8%) and did not differ between MDROpositive and MDRO-negative patients (34.1% [95% CI, 25.5%-42.7%] vs 32.3% [95% CI, 23.8%-42%], respectively; P 5 .698) (Fig. 3B) .
The most common cause of death in this cohort (109 of 264 deaths) was relapsed AML (62 of 264 patients, 56.9% of all deaths), followed by infection (28 of 264 patients, 25 .7% of all deaths), and GvHD (7 of 264 patients, 6 .4% of all deaths). A detailed description of the causes of death is provided in Supporting Table 2 (see online supporting information). Causes of death differed slightly, but not significantly, between colonized and Figure 2 . Kaplan-Meier curves illustrate overall survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT) (A) for all patients; (B) stratified for patients according to whether they were (dotted line) or were not (solid line) colonized; and (C) stratified for patients who were colonized by Gram-negative bacterial species (dashed line), colonized by Gram-positive bacterial species (dotted line), or and noncolonized.
noncolonized patients (P 5 .131), and death from infection was more frequent in colonized patients (30.6% vs 16.2% of all deaths).
In a multivariate analysis for OS ( Table 4 ) that included age >60 years (hazard ratio [HR], 1.409; 95% CI, 0.932-2.129; P 5 .104) and male sex (HR, 1.204; 95% CI, 0.808-1.795; P 5 .361), which revealed a different distribution in univariate analysis between colonized and noncolonized patients for disease stage (active disease vs CR: HR, 1.420; 95% CI, 0.971-2.078; P 5 .071) and adverse-risk cytogenetics (HR, 1.897; 95% CI, 1.264-2.848; P 5 .002), MDRO colonization was identified as an independent risk factor for fatal outcome (HR, 1.961; 95% CI, 1.307-2.943; P 5 .001) and, together with adverse-risk cytogenetics, was the only significant variable.
DISCUSSION
In the current study, we retrospectively analyzed data from 264 consecutive patients with AML who underwent their first allo-HSCT at our institution, and we investigated outcomes according to their MDRO colonization status (VRE, MDRGN, and MRSA). The study population was well balanced with regard to baseline patient characteristics, except for a male dominance in the colonized group. However, it is noteworthy that sex had no impact on OS in the multivariate analysis. It is also important to note that the cumulative incidence of relapse and the time from diagnosis or relapse to allo-HSCT did not differ between the colonized and noncolonized patients.
In this cohort of patients who underwent HSCT, 53.8% were colonized with at least 1 MDRO. Not many published data are available on the overall prevalence of MDRO colonization in HSCT recipients, possibly reflecting diverging MDRO monitoring practices and presumed regional differences in the prevalence of MDRO strains. In another report, the colonization rate was 31%, and lower rates were reported for MDRGN colonization (26% MDRGN colonization vs 14.4% MDRGN colonization in our study; 38 of 264 patients). 12 Obviously, the greater prevalence of MDRO colonization in our cohort was mainly attributable to VRE. Published data on VRE colonization during allo-HSCT vary from 16% to 36%. 14, 15, 29 We identified an overall VRE colonization rate of 46% (122 of 264 patients). These differences in VRE colonization prevalence might be explained by the underlying diseases and their pretransplantation treatment regimens, and, consequently, by differences in the administration of prophylactic and therapeutic anti-infective drugs like fluoroquinolones, which are a known risk factor for VRE Figure 3 . Charts illustrate the cumulative incidence of (A) nonrelapse-related mortality stratified for colonized (dotted line) and noncolonized (solid line) patients and of (B) relapse stratified for colonized (dotted line) and noncolonized (solid line) patients. Allo-HSCT indicates allogeneic hematopoietic stem cell transplantation. colonization. 30, 31 Another reason for the relatively high VRE prevalence in this cohort could be that Frankfurt is in the center of the so-called "VRE-belt," 32 which is a geographic high-prevalence VRE area.
Approximately one-third (30.3%) of all colonized patients experienced an MDRO infection, which is in line with other studies in the setting of allo-HSCT. Heidenreich et al reported an infection rate of 31%, 33 Bilinski et al reported 30%, 12 and Weinstock et al reported 34.2%
13 (for VRE), all in previously colonized patients. Liss et al described much lower rates of infection in previously colonized patients (infection rate: 6.6% with Gramnegative rods, 2% with VRE). 11 In their study, patients with all hematologic or oncologic malignancies were included; therefore, the results are not comparable to those from patients who undergo allo-HSCT, because they have a longer duration of neutropenia and a much higher risk of infections.
We identified colonization with an MDRO as an independent risk factor for fatal outcome after allo-HSCT (HR, 1.961; 95% CI, 1.307-2.943; P 5 .001). More patients in the colonized group died from infections than in the noncolonized group. These findings are in line with Bilinski et al, who demonstrated similar effects of MDRO in general after allo-HSCT in 106 patients with various hematologic diseases. 12 In our study, we demonstrate that VRE colonization is the main contributor to impaired OS, and we report data from a relatively large (n 5 264), homogenous sample of patients with AML who had a long follow-up. We hypothesized that colonized patients may develop hard-to-treat infections during the time immediately after allo-HSCT, which could result in a higher mortality rate from infections during periods of neutropenia. However, a negative impact of MDRO colonization on survival during neutropenia after allo-HSCT (0.8% vs 4.2%; P 5 .128) could not be confirmed. In contrast, OS at 6 months and thereafter was significantly different between the 2 groups. Thus, in terms of mortality, the crucial time for colonized patients appears to be the period as an outpatient after transplantation. One explanation for this phenomenon could be hard-to-treat infections in MDRO-positive patients caused by their colonizing organism. However, this explanation seems unlikely, because patients at our institution are closely followed in an outpatient unit; and, in case of fever or clinical suspicion of infection, patients in this cohort receive antibiotics with appropriate efficacy toward the individual, colonizing MDRO. Only 4 of 22 patients (18.2%) who had infectious-related deaths in the MDRO-positive group died from proven infections with an MDRO. It is more likely that patients within the colonized cohort may not be able to mount a full host defense against infections, although there were no significant differences in the length of immunosuppressive therapy between the 2 groups. One underlying disorder may be microbial dysbiosis, 34 for which MDRO colonization could be a surrogate marker that results from previous loss of microbiotal diversity, or vice versa, for which MDRO colonization could be a predisposing factor that paves the way for the overgrowth of certain bacteria species. Recently, the role of gut microbiota in the HSCT setting has received increasing attention, and it has been demonstrated that HSCT strongly alters the composition of gut microbiota. [35] [36] [37] [38] In our study, in almost all colonized patient (96.5%), the MDRO was detected by rectal swabs, suggesting loss of gut microbial diversity. 35, 39 The human gut microbiota interacts with the host's immune system, and a less diverse microbiome leads to an inadequate immune response. 40 In patients who still have an impaired immune system after allo-HSCT and after exposure to antibiotics, altered gut microbiota could hinder immune reconstitution and explain the higher rates of infectious-related deaths among colonized patients.
Here, we report that most patients were colonized by VRE, which was associated with significantly lower OS (64.3% [95% CI, 54.9%-73.7%] vs 34.2% [95% CI, 21.7%-46.7%]; P 5 .001). Enterococcus species may play a key role in microbiotal dysbiosis: during allo-HSCT, a shift toward Enterococcus species has been described. 36 Therefore, in patients with prior colonization, VRE may have a selection advantage and could mainly contribute to maintaining a less diverse gut microbiota. Furthermore, in VRE-colonized patients, VRE dominates the intestinal microbiota and is associated with the loss of microbiotal diversity. 41 Biagi et al revealed insights into regeneration of gut microbiota in pediatric patients after stem cell transplantation and demonstrated that the recovery of gut microbiota takes as long as 3 months 42 ; therefore, it seems likely that microbiotal-mediated immune dysregulation lasts during the outpatient period. The loss of diversity in human microbiota is associated with higher aGvHD rates and higher severity of GvHD. 12, 43, 44 Therefore, the hypothesis of microbiotal dysregulation in colonized patients is strengthened by the finding of a slightly higher cumulative incidence of aGvHD and significantly more severe aGvHD (severe, grade 3) in colonized patients (13.5% vs 5%; P 5 .020). However, we have to take into account that our study is retrospective, and no general conclusion for other cohorts can be drawn.
Original Article
Therefore, in view of the probability of worse OS in colonized patients, all efforts should be made to minimize colonization with MDROs before allo-HSCT. It is well known that frequent prophylactic and therapeutic administration of antibiotics results in higher rates of colonization with MDRO. 45, 46 For instance, prophylaxis with fluoroquinolones, which are used routinely during AML induction at our center, is associated with the occurrence of MDRO. 47, 48 Therefore, for instance, prophylactic antibiotic regimens should be revisited, and the use of antimicrobial agents before allo-HSCT should be handled as strictly as possible, because allogeneic transplantation without prophylactic antibiotics seems to be feasible. 49 In addition, the use of reserve antibiotics might be limited if they are under the control of an antibiotic stewardship program. 50 Furthermore, prospective studies are needed to clarify the association of intestinal microbiota, MDRO colonization, and patient outcomes. 
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